- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of January 6
The Center for Biosimilars® recaps the top stories for the week of January 6.
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 6, 2019.
Number 5: A recent study finds that peer influence factors heavily into whether oncologists decide to adopt bevacizumab for their patients.
Number 4: The FDA notes the approval of 10 biosimilars in its 2019 report of drug approvals, which included 48 novel drugs.
Number 3: A look back at the top 5 legal stories in 2019 finds that cases involving adalimumab featured in 2 of them.
Number 2: Novo Nordisk takes 3 steps to improve insulin affordability, and says the FDA expanded use of its fast-acting mealtime insulin to children as young as 2.
Number 1: Pfizer says it is launching its bevacizumab biosimilar, Zirabev, in the United States.
To read all of these articles and more, visit centerforbiosimilars.com.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
August 1st 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
August 1st 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
